Zobrazeno 1 - 10
of 86
pro vyhledávání: ''
Autor:
Rama Suresh, Kian-Huat Lim, Shahed N. Badiyan, Lauren E. Henke, Steven R. Hunt, Yi Huang, Hyun Jik Kim, Benjamin R. Tan, Haeseong Park, Matthew L. Silviera, Matthew G. Mutch, Paul E. Wise, Katrina S. Pedersen, R.I. Chin, Matthew A. Ciorba, Parag J. Parikh, Sean C. Glasgow, Manik Amin, Andrea Wang-Gillam, Jeffrey R. Olsen, Michael C. Roach
Publikováno v:
Clinical colorectal cancer. 20(3)
Purpose Short-course radiation therapy (SCRT) and nonoperative management are emerging paradigms for rectal cancer treatment. This clinical trial is the first to evaluate SCRT followed by chemotherapy as a nonoperative treatment modality. Methods Pat
Autor:
Maryam Soleimani, Jennifer L. Spratlin, Shirin Abadi, Sharlene Gill, Karen E. Mulder, Aaron Sha, Winson Y. Cheung, Maria Yi Ho, Jonathan M. Loree, Hagen F. Kennecke
Publikováno v:
Clinical Colorectal Cancer. 17:156-163
710 Background: CAPOX and FOLFOX are used interchangeably in the adjuvant treatment of colon cancer despite the lack of comparative phase III trials.We aimed to compare toxicities, relative dose intensity (RDI), disease free (DFS) and overall surviva
Autor:
Antoine Hollebecque, Mohamed Hebbar, Franck Bonnetain, Sophie Paget-Bailly, Farid El-Hajbi, Charlotte Peugniez, Anne Ploquin, Anthony Turpin
Publikováno v:
Clinical Colorectal Cancer. 17:e99-e107
Background We studied the relationship between intermediate criteria and overall survival (OS) in metastatic colorectal cancer (mCRC) patients who received first-line chemotherapy with bevacizumab. Patients and Methods We assessed OS, progression-fre
Autor:
Juliana Guareschi dos Santos, Michel Fabiano Silva Alves, Renata de Almeida Coudry, Sheila Aparecida Coelho Siqueira, Paulo M. Hoff, Rachel P. Riechelmann, Alexandra Khichfy Alex
Publikováno v:
Clinical Colorectal Cancer. 16:228-239
Background DNA deficient mismatch repair (dMMR) genes are associated with microsatellite instability and good prognosis in early-stage colorectal cancer (CRC). However dMMR is rare in metastatic CRC (mCRC) and little is known about its influence on t
Autor:
Manish Bhandare, Prachi Patil, Vishwas Pai, Rahul Bhamre, Reena Engineer, Vikas Ostwal, Avanish Saklani
Publikováno v:
Clinical Colorectal Cancer. 16:e1-e6
Peritoneal carcinomatosis (PC) from colorectal cancers (CRC) either at initial presentation or at subsequent recurrence presents a significant treatment challenge. The aim of our study was to find its incidence and analyze outcomes of patients with P
Autor:
Toshihiko Doi, Takayuki Yoshino, Atsushi Ohtsu, Takashi Kojima, Shota Fukuoka, Masaaki Noguchi, Yasutoshi Kuboki, Kohei Shitara, Akihito Kawazoe, Hedeaki Bando, Wataru Okamoto
Publikováno v:
Clinical Colorectal Cancer. 16:e39-e44
Fatigue is the most common toxicity of all grade toxicities with regorafenib, was the second most common toxicity in the CORRECT (regorafenib monotherapy for previously treated metastatic colorectal cancer) study, and is a major reason for early dose
Publikováno v:
Clinical Colorectal Cancer. 15:292-297
Within the past several years, no chemotherapy has been sufficient to increase the overall survival of patients with chemorefractory colorectal cancer. TAS-102 (Lonsurf) is an oral fluoropyrimidine that is formed by the combination of 2 active drugs:
Autor:
Jacopo Giuliani, Andrea Bonetti
Publikováno v:
Clinical Colorectal Cancer. 15:277-284
In light of the relevant expenses of pharmacologic interventions, it might be interesting to make a balance between the cost of the new drugs administered and the difference in progression-free survival in first-line treatments for advanced colorecta
Autor:
Federica Ravera, Salvatore Siena, Laura Palmeri, Katia Bencardino, Gianluca Mauri, Alessio Amatu, Elisa Boiani, Erica Bonazzina, Andrea Sartore-Bianchi, Federica Tosi, Marialuisa Querques, Alberto Menegotto
Publikováno v:
Clinical Colorectal Cancer. 15:213-221
Oxaliplatin immune-induced syndrome (OIIS) is an uncommon, potentially life-threatening, side effect associated with oxaliplatin-based chemotherapy. The present study reports 5 original cases of OIIS and systematically reviewed the available publishe
Autor:
Yasutoshi Kuboki, Atsushi Ohtsu, Takayuki Yoshino, Toshihiko Doi, Hideaki Bando, Akihito Kawazoe, Takashi Kojima, Kohei Shitara, Shota Fukuoka, Daisuke Kotani, Wataru Okamoto
Publikováno v:
Clinical Colorectal Cancer. 15:e109-e115
Background The combination drug TAS-102 is a novel oral nucleoside antitumor agent containing trifluridine and tipiracil hydrochloride, which prevents the degradation of trifluridine. The global phase III RECOURSE trial (Study of TAS-102 in Patients